Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-4642 + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
HRS-4642 + nab-paclitaxel + gemcitabine is an investigational combination therapy developed by Shanghai Hengrui Pharmaceutical Co., Ltd. for the treatment of advanced or metastatic pancreatic adenocarcinoma harboring the KRAS G12D mutation. This regimen combines HRS-4642, a potent and highly selective small molecule inhibitor of the KRAS G12D mutant protein, with the standard cytotoxic chemotherapy backbone of nab-paclitaxel (an albumin-bound formulation of paclitaxel that inhibits microtubule disassembly) and gemcitabine (a nucleoside analog that inhibits DNA synthesis). By targeting the most common oncogenic driver in pancreatic cancer alongside traditional chemotherapy, the combination aims to provide synergistic anti-tumor activity and overcome resistance mechanisms. It is currently being evaluated in Phase Ib/II clinical trials, both as a triplet and in combination with immunotherapy.
- Other names
- HRS-4642 + albumin-bound paclitaxel + gemcitabine
02
Targets
TUBB (Tubulin (alpha and beta subunits))KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)DNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on HRS-4642 + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-4642 + nab-paclitaxel + gemcitabine.